Monthly Archives: October 2011

Protease inhibitors (PIs)

Posted on October 18, 2011 by admin

A clear understanding of the key sites of action for the newer antiviral compounds in development is of outmost importance. HCV is a positive-sense single-stranded RNA virus, meaning that its genome can function directly as a template for viral protein … Continue reading →

Posted in Other | Leave a comment

Searching for new antiviral therapies. Part 3

Posted on October 13, 2011 by Fred Smith

Albinterferon (Zalbin

Posted in Diseases | Leave a comment

Searching for new antiviral therapies. Part 2

Posted on October 12, 2011 by Fred Smith

However, not all patients may benefit from these new types of IFNs. In particular, it seems unlikely that patients with strong contraindications to the current IFNs will be eligible for treatment with newer formulations, even if the AEs profiles of … Continue reading →

Posted in Diseases | Leave a comment

Searching for new antiviral therapies

Posted on October 12, 2011 by admin

Candidates for new therapeutic approaches The current Standard of Care (SoC) combination therapy for chronic hepatitis C (CHC) is limited by its insufficient efficacy in some patient groups, the drug side-effects and contraindications and the high associated costs. There are … Continue reading →

Posted in Diseases | Leave a comment

HIV-HCV coinfection

Posted on October 11, 2011 by admin

Because of shared risk factors, HCV co-infection is common (10-40%) among HIV-infected persons. HIV infection accelerates the progression to advanced fibrosis and cirrhosis and increases the risk for liver-related complications, including hepatocellular carcinoma compared with HCV monoinfected patients. As a … Continue reading →

Posted in Diseases | Leave a comment